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 With the introduction of high-definition colonoscopes and virtual 
chromoendoscopy, evaluating the surface pit pattern and vascular pattern of colorectal 
lesions is now possible. This has empowered endoscopists, through the utilization of 
established optical evaluation criteria(1, 2), to reliably diagnose and distinguish between 
diminutive adenomatous and hyperplastic polyps.  
However, with the widespread adoption of virtual chromoendoscopy, a common 
occurrence after high-confidence optical diagnosis of a diminutive adenoma is a 
conflicting pathologic diagnosis(3); whereby the pathologist has only identified normal 
colorectal tissue. This discrepancy is of critical importance, given its inherent effect on 
surveillance colonoscopy recommendations(4), and therefore its potential impact on 
interval colorectal cancer. In a recent study by Ponugoti and colleagues(5), 644 
consecutive colorectal lesions ≤ 3mm were diagnosed as adenomas with high-
confidence by an experienced endoscopist with expertise in optical evaluation. On 
pathology, 15.4% were diagnosed as normal mucosa. Two blinded optical evaluation 
experts subsequently reviewed high-quality lesion images and agreed with the 
endoscopic diagnosis in 94% and 100% of cases, respectively. These findings directly 
question pathology as the gold-standard for diagnosing lesions ≤ 3mm in size.  
 Recently, artificial intelligence (AI) has showcased an impressive ability to 
diagnose diminutive adenomatous polyps(6, 7). Therefore, we sought to evaluate the 
discrepancy between endoscopic and pathologic diagnoses of lesions ≤ 3mm using an 
established real-time AI clinical decision support solution (CDSS).  
 
Methods 
 From April 2016 to August 2017 consecutive colorectal lesions ≤ 3mm, 
diagnosed during optical evaluation as adenatomous with high-confidence by a single 
experienced endoscopist with expertise in optical evaluation (DKR), were considered for 
inclusion(5). A size restriction of ≤ 3mm was selected, as these lesions were perceived to 
have a substantial risk of failed pathologic identification. 
Endoscopy was performed using high-definition Olympus 190 series 
colonoscopes (Olympus America Corp., Pennsylvania, USA) with evaluation under 
white-light, narrow-band imaging (NBI) and near-focus, when available. High-confidence 
optical diagnosis was performed using the NBI International Colorectal Endoscopic 
(NICE) classification(1). After image capture, the lesion was removed either by cold 
forceps or cold snare polypectomy. Specimen collection and preparation was 
protocolized, in accordance with the College of American Pathologists. Pathology 
review was performed by one of 17 board-certified pathologists. Blinded to pathology, 
one endoscopist (DKR) reviewed all captured images and removed those of suboptimal 
quality. Institutional review board (IRB) approval was obtained.  
 Our CDSS, using a deep convolutional neural network, was previously trained, 
validated and tested on routine unaltered videos of normal mucosa and colorectal 
polyps captured by Olympus 190 series high-definition colonoscopes(7). It allows for 
real-time NICE classification for both images and videos with published performance 
achieving the American Society for Gastrointestinal Endoscopy (ASGE) Preservation 
and Incorporation of Valuable Endoscopic Innovations (PIVI) 2 recommendation(8). The 
image dataset was evaluated by our CDSS, which was blinded to the endoscopic and 
pathologic diagnoses.  
 Our primary outcome was to assess the frequency of agreement between 
endoscopic, pathologic and CDSS diagnoses (Figure 1). SPSS version 25.0 (IBM Corp, 
New York, USA) was used for data analysis.  
 
Results 
900 consecutive colorectal lesions ≤ 3mm, with a high-confidence optical 
diagnosis of adenoma were evaluated. 256 lesions were excluded due to sub-optimal 
image quality.  
Of the remaining 644 lesions, 458 (71.1%) had a concordant pathologic 
diagnosis. Discrepancy between endoscopic and pathologic diagnoses occurred in 186 
(28.9%) lesions. This included a pathologic diagnosis of hyperplastic polyp, sessile 
serrated polyp and normal mucosa in 85 (13.2%), 2 (0.3%), and 99 (15.4%), 
respectively.   
Endoscopic, pathologic and CDSS diagnoses are provided in supplementary 
table 1. Overall, CDSS agreed with the endoscopic diagnosis in 577 (89.6%) lesions. 
Concerning discordant endoscopic and pathologic diagnoses, CDSS agreed with the 
endoscopic diagnosis in 168 (90.3%) lesions. Of those lesions identified on pathology 





 Discordance between endoscopic and pathologic diagnoses for colorectal lesions 
is not infrequent. This represents a clinically and fiscally meaningful scenario where the 
endoscopist must decide on the appropriate surveillance interval. Our findings further 
support those of Ponugoti et al.(5), and represent a paradigm shift; pathology should not 
be viewed as the gold standard for diagnosing colorectal lesions ≤ 3mm.  
 Potential sources for this discrepancy are many. Although optical 
misclassification, and erroneously resecting adjacent normal tissue are possible, it is 
unlikely for them to be key players. All examinations were performed by an experienced 
endoscopist with expertise in optical evaluation. Likewise, a pathologist diagnosing 
normal colorectal mucosa when a high-confidence optical diagnosis of adenoma has 
been made seems improbable. Therefore, specimen retrieval and specimen processing 
appear to be likely culprits; whereby tissue fragmentation leads to the collection and 
evaluation of a single piece of normal colorectal epithelium or sub-optimal sectioning 
causes the pathologist to believe that only normal colorectal epithelium is present in the 
specimen, respectively. Further evaluations to confirm these findings, assess potential 
endoscopist-, pathologist- and processing-related factors for this discrepancy, address 
limitations of this current analysis, and assess the impact on surveillance intervals are 
needed. This will need to include: 1) photo-documentation of optical evaluation and 
appropriate tissue resection; 2) specimen quality and tissue fragmentation assessment; 
3) specimen re-sectioning and 4) assessing endoscopic and pathologic inter-rater 
reliability.  
 This study is the first description of a potential future application of AI; the 
arbitration between endoscopist and pathologist when discordant diagnoses occur. 
CDSS performance will need to be optimized with evidence showcasing that it can 
effectively arbitrate between endoscopic and pathologic diagnoses prior to 
consideration for clinical practice. CDSS performance optimization is, however, 
inevitable, given the increasing use of deep learning methodology in the development of 
current AI platforms, manifesting in AI’s ability to adapt with increasing data exposure.  
In summary, our findings reaffirm that pathology should be questioned as the 
gold standard for diagnosing colorectal lesions ≤ 3mm; especially, when high-
confidence optical evaluation identifies an adenoma. It is therefore imperative that all 
endoscopists incorporate optical evaluation, coupled with high-quality photo 
documentation, into clinical practice. In the interim, endoscopists should consider a 
more conservative approach for deciding on the appropriate surveillance colonscopy 
interval, when endoscopic and pathologic discrepancy is encountered.  
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Figure Legends 
Figure 1: A: 3mm colorectal lesion optically diagnosed with high-confidence as 
adenomatous; B: histopathology identifies only normal mucosa; C: CDSS supports the 
optical diagnosis 

Supplementary Table 1: Pathologic and CDSS diagnoses for 644 colorectal lesions ≤ 




Hyperplastic Polyp Adenoma Normal Mucosa 
Adenoma (N=458) 18 (3.9%) 409 (89.3%) 31 (6.8%) 
Normal Mucosa (N=99) 5 (5.1%) 90 (90.9%) 4 (4.0%) 
Hyperplastic Polyp (N=85) 3 (3.5%) 76 (89.4%) 6 (7.1%) 
Sessile Serrated Polyp (N=2) 0 (0.0%) 2 (100.0%) 0 (0.0%) 
 
 
